Is Thymosin Alpha-1 Legal in Maryland?

What Thymosin Alpha-1 Is and Why Legality Is Complicated

Thymosin Alpha-1 is a 28-amino-acid peptide derived from thymosin fraction 5, first isolated by Allan Goldstein's lab in the 1970s. Its synthetic form, thymalfasin, is approved in more than 35 countries for hepatitis B, hepatitis C, and as an immune adjuvant, but the FDA has never granted it approval as a finished pharmaceutical product in the United States. [1]

That single fact drives almost every legal question Maryland residents ask about Ta1.

The Difference Between "Unapproved" and "Illegal"

An unapproved drug is not automatically illegal for a physician to prescribe or a compounding pharmacy to prepare. The Federal Food, Drug, and Cosmetic Act (FD&C Act) gives licensed pharmacies and outsourcing facilities narrow but real pathways to compound drugs that lack finished-drug approval, provided specific conditions are met. [2]

The word "unapproved" means the FDA has not reviewed a sponsor's New Drug Application (NDA) for Ta1 in the United States. It does not mean a physician commits a crime by prescribing it or a patient commits a crime by possessing it under a valid prescription.

Why the Gray Area Exists

Ta1 is not a controlled substance under the Controlled Substances Act. The DEA has assigned it no schedule. [3] The legal complexity comes entirely from FDA compounding rules, specifically which bulk drug substances may lawfully be used as starting material for compounded preparations.

Federal Framework: FDA, the Bulks List, and Compounding Law

Understanding federal law is necessary before discussing Maryland specifically, because Maryland has no independent statute that overrides it.

Section 503A: Traditional Compounding Pharmacies

Section 503A of the FD&C Act governs traditional compounding pharmacies that dispense patient-specific preparations pursuant to individual prescriptions. [2] A 503A pharmacy may compound using bulk drug substances only if:

1. The substance appears on the FDA's positive list (substances that may be used), or
2. The substance is not on the FDA's negative list (substances that may not be used), or
3. The substance is a component of an FDA-approved drug.

Ta1 does not appear on the current positive list for 503A compounding. The FDA has evaluated Ta1 and placed it on the list of bulk substances that raise significant safety, effectiveness, or compounding concerns, meaning 503A pharmacies face real regulatory risk if they compound it without further FDA action. [4]

Section 503B: Outsourcing Facilities

Section 503B outsourcing facilities may produce larger batches without patient-specific prescriptions, but they operate under even stricter bulk-substance rules. [5] The FDA publishes a separate list of bulk substances for 503B facilities. Ta1 has not been placed on the FDA's 503B bulk substances list as a substance that may be used, which means 503B facilities cannot lawfully use it as a starting material under current guidance. [6]

What the FDA's Evaluation Actually Found

The FDA's 2019 proposed rule and associated documents evaluated thymosin alpha-1 for the 503A bulks list and noted that, while thymalfasin has a pharmacological basis for immune modulation, the absence of an approved U.S. Product and unresolved questions about clinical evidence in U.S. Patient populations weighed against placing it on the positive list. [4] The agency has not issued a final rule closing this question permanently, so the status remains subject to revision.

The FDA's Center for Drug Evaluation and Research (CDER) guidance on compounding makes clear that compounding a drug that is essentially a copy of a commercially available approved drug, or compounding from bulk substances not on the positive list, exposes pharmacies to enforcement risk. [7]

Research Use vs. Clinical Use

Researchers at accredited institutions can obtain Ta1 as a research chemical under Investigational New Drug (IND) exemptions or institutional review board protocols. [8] That pathway is entirely separate from clinical prescribing and does not give individual patients legal access outside a formal clinical trial.

Maryland State Law: What the State Adds (and Does Not Add)

Maryland has not enacted a statute that specifically addresses Thymosin Alpha-1, peptide therapy broadly, or thymalfasin by name. The state's legal framework relevant to Ta1 involves three bodies:

Maryland Board of Pharmacy

The Maryland Board of Pharmacy licenses and regulates all pharmacies operating in the state, including compounding pharmacies. [9] Maryland-licensed 503A compounding pharmacies must comply with both state board rules and federal FD&C Act requirements. The Board has not issued a specific advisory or bulletin on Ta1 as of the date of this article's last review. Because Maryland does not have a positive list that expands on the federal one, federal restrictions on compounding Ta1 apply to every Maryland pharmacy.

Maryland Medical Practice Act

The Maryland Medical Practice Act (Health Occupations Article, Title 14) governs licensed physicians. [10] It does not list Ta1 as a prohibited prescription item, nor does it grant affirmative permission. A physician who prescribes Ta1 through a compounding pharmacy that cannot lawfully prepare it could face scrutiny for prescribing a preparation that the pharmacy was not authorized to compound, but the prescribing act itself is not independently criminalized by state statute.

Maryland Controlled Dangerous Substances Act

Ta1 is not listed under the Maryland Controlled Dangerous Substances Act. [11] Possession without a valid prescription does not carry the criminal penalties that apply to scheduled substances. The legal exposure for patients obtaining Ta1 outside a proper medical framework is primarily civil and regulatory, not criminal, though obtaining any pharmaceutical compound through unlicensed channels carries other risks.

The practical framework a Maryland prescriber should apply:

1. Confirm the compounding pharmacy holds a current Maryland Board of Pharmacy license and, if applicable, an FDA registration as a 503B outsourcing facility.
2. Verify the pharmacy has obtained Ta1 from an FDA-registered bulk manufacturer with a valid Certificate of Analysis.
3. Document the clinical rationale thoroughly in the patient record because neither FDA nor the Maryland Board provides a formal safe harbor for Ta1 compounding under current rules.
4. Monitor the FDA's bulk substances lists for updates, as the agency periodically revises both 503A and 503B lists.

Clinical Background: Why Patients and Physicians Are Interested

Ta1's legal complexity has not dampened clinical interest. The peptide modulates both innate and adaptive immunity by stimulating dendritic cell maturation, enhancing natural killer cell activity, and promoting T-helper 1 cytokine responses. [12]

Evidence in Infectious Disease

A randomized controlled trial published in the Journal of Viral Hepatitis (N=150) found that thymalfasin combined with pegylated interferon alfa-2a produced significantly higher rates of sustained virologic response in hepatitis C genotype 1 patients compared with interferon alone. [13] Separately, a systematic review of 26 trials in hepatitis B found thymalfasin superior to placebo for HBeAg seroconversion (relative risk 1.68, 95% CI 1.29 to 2.18). [14]

Evidence in Sepsis and Critical Illness

A 2019 multicenter trial (N=361) published in Intensive Care Medicine assessed thymalfasin in patients with sepsis-associated immunosuppression and reported a 28-day mortality reduction from 30.8% to 20.0% compared with placebo (P<0.05), though the authors noted the need for replication in larger cohorts. [15]

Evidence in Oncology and Vaccine Adjuvancy

The American Society of Clinical Oncology's annual meeting has featured multiple abstracts examining Ta1 as an adjunct to checkpoint inhibitor therapy, with preliminary data suggesting it may reduce treatment-related immune exhaustion. [16] Formal phase III data in U.S. Patients remain absent, which is one reason the FDA has not advanced an NDA.

What the Evidence Does Not Yet Establish

No phase III trial has been conducted exclusively in U.S. Patients under FDA oversight for any of these indications. The National Institutes of Health ClinicalTrials.gov database lists several completed or ongoing studies, but most are international. [17] Absence of a U.S.-based NDA is the direct regulatory consequence of this evidence gap.

How to Legally Obtain Thymosin Alpha-1 in Maryland

Given the regulatory framework above, a Maryland resident has a narrow but real pathway to access Ta1 through legitimate medical channels.

Step 1: Establish Care With a Licensed Prescriber

A Maryland-licensed physician, nurse practitioner, or physician assistant with prescribing authority must evaluate the patient and determine that Ta1 serves a legitimate clinical purpose. Telehealth prescribing is permitted in Maryland for most non-controlled substances, provided the prescriber meets standard-of-care requirements under the Maryland Telehealth Law (Health General Article, Section 19-319). [18]

Step 2: Identify a Compliant Compounding Pharmacy

The prescriber or patient should verify that the compounding pharmacy:

• Holds a current license from the Maryland Board of Pharmacy or is properly registered to ship into Maryland from another state
• Follows United States Pharmacopeia (USP) Chapter 797 sterile compounding standards, since Ta1 is typically administered by subcutaneous injection [19]
• Sources Ta1 bulk substance from a supplier that is registered with the FDA as a bulk drug substance manufacturer and can provide a Certificate of Analysis

The FDA's warning letters database is publicly searchable and reveals which pharmacies have faced enforcement for compounding unapproved bulk substances. Patients should ask their pharmacy whether it has received any FDA warning letters related to peptide compounding. [20]

Step 3: Understand the Regulatory Risk Disclosure

Because Ta1 is not on the FDA's positive list for 503A compounding, a fully transparent prescriber will document in the patient chart that Ta1 is being prescribed off the positive list, that the patient has been counseled about this regulatory status, and that a clinical rationale exists. This documentation protects both prescriber and patient if questions arise later.

What to Avoid

Purchasing Ta1 labeled "for research use only" from online chemical suppliers without a physician prescription is not a compliant pathway for human use. The FDA has sent multiple untitled letters and warning letters to suppliers marketing peptides in this manner. [21] Products sourced this way lack pharmaceutical-grade quality controls, may contain incorrect concentrations, and create real safety risk separate from the legal question.

Dosing Context for Clinical Discussions

Maryland prescribers and patients often ask about typical dosing as part of understanding whether a pharmacy's preparation is reasonable. Published clinical trials have used thymalfasin at 1.6 mg subcutaneously twice weekly, the dose studied in most hepatitis and sepsis trials. [13, 15] Some integrative medicine practitioners use lower maintenance doses of 0.8 mg two to three times weekly, though this specific regimen has less controlled-trial support. Duration in published trials has ranged from 6 months (hepatitis B protocols) to the duration of ICU stay (sepsis protocols).

These figures are provided for context, not as prescribing recommendations. Any dosing decision requires individualized physician assessment.

Telehealth Access in Maryland: Specific Considerations

Maryland adopted updated telehealth parity rules following the COVID-19 public health emergency, and those rules remain in effect. [18] A patient in Maryland can legally receive a telehealth consultation from a Maryland-licensed or properly authorized out-of-state prescriber, obtain a prescription for a compounded preparation, and have that preparation shipped to a Maryland address from a licensed out-of-state compounding pharmacy, provided that pharmacy is registered to do business in Maryland.

The Maryland Board of Pharmacy requires out-of-state non-resident pharmacies to hold a Non-Resident Pharmacy Permit. [9] Patients should verify this permit before accepting a shipment. Receiving a compounded injectable from an unlicensed pharmacy violates Maryland pharmacy law regardless of the underlying substance's federal status.

Physician Perspective on Risk-Benefit in the Current Regulatory Climate

The absence of FDA approval does not automatically make a treatment inappropriate for a given patient, but it does place a higher burden of documentation on the prescriber. Board-certified physicians practicing functional or integrative medicine in Maryland who prescribe Ta1 typically cite the published international trial data, obtain informed consent that explicitly describes the unapproved status of the compounded preparation, and monitor patients with periodic immune panel testing (CD4/CD8 ratios, NK cell activity) to assess response.

The Endocrine Society's 2021 position statement on compounded hormone therapy, while addressing a different drug class, articulates a general principle applicable here: compounded preparations should be reserved for patients with a documented clinical need that cannot be met by an FDA-approved product, and prescribers bear responsibility for ensuring the compounding pharmacy meets quality standards. [22]

Comparison: Ta1 vs. Other Peptides Under Maryland Law

Understanding where Ta1 sits relative to other commonly prescribed peptides helps clarify its specific position.

| Peptide | FDA Status | 503A List Status | DEA Schedule | Maryland-Specific Law | |---|---|---|---|---| | Thymosin Alpha-1 | Not approved (US) | Not on positive list | None | No independent statute | | BPC-157 | Not approved | Not on positive list | None | No independent statute | | Sermorelin | Not approved (compounded) | Positive list (503A) | None | No independent statute | | Tesamorelin | FDA-approved (Egrifta) | N/A (approved drug) | None | Standard prescription law | | PT-141 (Bremelanotide) | FDA-approved (Vyleesi) | N/A (approved drug) | None | Standard prescription law |

Sermorelin's presence on the 503A positive list illustrates the difference Ta1's absence makes. A 503A pharmacy can compound sermorelin with lower regulatory risk than it can compound Ta1. [4]

Ongoing Regulatory Developments to Watch

The FDA's process for evaluating bulk substances under 503A is ongoing. The agency accepts public comment during notice-and-comment rulemaking periods and has revised its lists before. Patients and prescribers with a clinical interest in Ta1 should monitor the FDA's compounding webpage for updates. [7]

The International Peptide Society and several integrative medicine organizations have submitted public comments to the FDA supporting placement of Ta1 on the 503A positive list, citing the volume of international evidence. Whether the FDA acts on those submissions is uncertain as of the publication date of this article.